跳至主要内容
临床试验/JPRN-UMIN000032045
JPRN-UMIN000032045已完成未知

Questionnaire Survey on the Use of Depot Formulation of Leuprorelin Acetate Injection in Patients with Prostate Cancer (QLIPP) - Questionnaire Survey on Leuprorelin use in prostate cancer patients

Matsuyama Red Cross Hospital0 个研究点目标入组 127 人开始时间: 2018年4月1日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
127

研究概览

简要总结

Fifty-seven percent of patients and 65% of caregivers showed a strong preference for the 6M formulation compared with the 3M formulation. There was no difference in the percentage of strong preference between the two groups, Among caregivers, there was a strong preference for the 6M drug in those who had to accompany their patients to the hospital (p<0.001). T

研究设计

研究类型
Observational

入排标准

年龄范围
ot applicable 至 ot applicable(—)
性别
Male

入选标准

  • 未提供

排除标准

  • 1.Patients who have never prescribed luteinizing hormone-releasing hormone (LH-RH) agonist/LH-RH antagonist luteinizing hormone-releasing hormone (LH-RH) agonist/LH-RH antagonist 2.Caregivers of patients who cannot agree to participate in the study 3.Investigators, near relatives of investigators, investigator assistant, or near relatives of investigator assistant. 4.Who were judged clinically that responses to the questionnaire are improper or unsuitable by the principal investigator or collaborating physicians. 5.Who reject the participation of the study 6.Who wish to withdraw after the consent 7.When a false entry is identified

研究者

相似试验

Questionnaire Survey on the Use of Depot Formulation... | 临床试验